Preparation, characterization and in vivo evaluation of curcumin self-nano phospholipid dispersion as an approach to enhance oral bioavailability

International Journal of Pharmaceutics

Volumn 489, Issue 1-2, 2015, Pages 117-123

  Allam, Ahmed N ^a   Komeil, Ibrahim A ^b   Fouda, Mohamed A ^a   Abdallah, Ossama Y ^a  

^a Alexandria University Faculty of Pharmacy   (Egypt)

^b Medizen Pharmaceutical Industries   (Egypt)

Author keywords

Bioavailability; Curcumin; In vivo evaluation; Nano Dispersion; Phospholipid

Indexed keywords

CURCUMIN; MEDIUM CHAIN TRIACYLGLYCEROL; MIGLYOL; NANOCARRIER; PHOSAL 53; PHOSPHOLIPID DERIVATIVE; SELF NANO PHOSPHOLIPID DISPERSION; SOLUBILIZER; SURFACTANT; UNCLASSIFIED DRUG; CREMOPHOR; GLYCEROL; MACROGOL DERIVATIVE; PHOSPHOLIPID; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DILUTION; DISPERSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; EVALUATION STUDY; IN VITRO STUDY; IN VIVO STUDY; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; PHASE SEPARATION; PHYSICAL CHEMISTRY; PRECIPITATION; PRIORITY JOURNAL; RAT; SUSPENSION; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; ANIMAL; BIOAVAILABILITY; CHEMISTRY; WISTAR RAT;

ANIMALS; BIOLOGICAL AVAILABILITY; CURCUMIN; DRUG COMPOUNDING; GLYCEROL; PHOSPHOLIPIDS; POLYETHYLENE GLYCOLS; RATS, WISTAR; SURFACE-ACTIVE AGENTS; TRIGLYCERIDES;

EID: 84929996859     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2015.04.067     Document Type: Article

References (38)

1. M. Agacha, S. Delbaereb, S. Marinkovic, B. Estrine, and V. Nardello-Ratajc Synthesis characterization, biodegradability and surfactant properties of bio-sourced lauroyl poly(glycerol-succinate) oligoesters Colloids Surf. A: Physicochem. Eng. Aspects 419 2013 263 273
2. R.P. Carlson, D.A. Hartman, S.J. Ochalski, and J.L. Zimmerman Sirolimus (rapamycin, Rapamune) and combination therapy with cyclosporin A in the rat developing adjuvant arthritis model: correlation with blood levels and the effects of different oral formulations Inflamm. Res. 47 1998 339 344
3. A. Chudasama, V. Patel, M. Nivsarkar, K. Vasu, and C. Shishoo A Novel lipid-based oral drug delivery system of Nevirapine Int. J. Pharm. Tech. Res. 3 2011 1159 1168
4. Y.S. Elnaggar, M.A. El-Massik, and O.Y. Abdallah Self-nanoemulsifying drug delivery systems of tamoxifen citrate: design and optimization Int. J. Pharm. 380 2009 131 141
5. M.A. Elsheikh, Y.S. Elnaggar, E.Y. Gohar, and O.Y. Abdallah Nanoemulsion liquid preconcentrates for raloxifene hydrochloride: optimization and in vivo appraisal Int. J. Nanomed. 7 2012 3787 3802
6. E. Fouad, M. El-Badry, M. Mahrous, A. Alsarra, Z. Alashbban, and K. Alanzi In vitro investigation for embedding dextromethorphan in lipids using spray drying Dig. J. Nanomater. Bios. 6 2011 1129 1139
7. M.S. Freag, Y.S. Elnaggar, and O.Y. Abdallah Lyophilized phytosomal nanocarriers as platforms for enhanced diosmin delivery: optimization and ex vivo permeation Int. J. Nanomed. 8 2013 2385 2397
8. G. Fricker, T. Kromp, A. Wendel, A. Blume, J. Zirkel, H. Rebmann, C. setzer, R.-O. Quikert, F. Martin, and C. Müller-Goymann Phospholipids and lipid-based formulations in oral drug delivery Pharm. Res. 27 2010 1469 1486
9. C. Fruijtier-Pölloth Safety assessment on polyethylene glycols (PEGs) and their dervatives as used in cosmetic products Toxicology 214 2005 1 38
10. Z. Ge, X. Zhang, L. Gan, and Y. Gan Redispersible, dry emulsion of lovastatin protects against intestinal metabolism and improves bioavailability1 Acta Pharm. Sinica 29 2008 990 997
11. H. Gelderblom, J. Verweij, K. Nooter, and A. Sparreboom Cremophore EL: the drawbacks and advantages of vehicle selection for drug formulation Eur. J. Cancer 37 2001 1590 1598
12. T. Gershanik, and S. Benita Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs Eur. J. Pharm. Biopharm. 50 2005 179 188
13. S. Gupta, S. Chavhan, and K.K. Sawant Self-nanoemulsifying drug delivery system for adefovir dipivoxil: design characterization, in vitro and ex vivo evaluation Colloids Surf. A: Physicochem. Eng. Aspects 392 2011 145 155
14. D.J. Hauss Oral lipid-based formulations Adv. Drug Deliv. Rev. 59 2007 667 676
15. S.X. Hu, R. Soll, S. Yee, D.L. Lohse, A. Kousba, B. Zeng, X. Yu, A. McPherson, J. Renick, J. Cao, A. Tabak, J. Hood, J. Doukas, G. Noronha, and M. Martin Metabolism and pharmacokinetics of a novel Src kinase inhibitor TG100435 ([7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-y l-ethoxy)-phenyl]-amine) and its active N-oxide metabolite TG100855 ([7-(2,6-dichloro-phenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-{4-[2-(1-oxy-pyrrolid in-1-yl)-ethoxy]-phenyl}-amine) Drug Metab. Dispos. 35 2007 929 936
16. C. Ireson, S. Orr, D. Jones, R. Verschoyle, C. Lim, J. Luo, L. Howells, S. Plummer, R. Jukes, M. Williams, W. Steward, and A. Gescher Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in-vivo and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production Cancer Res. 61 2001 1058 1064
17. F. Khan, M.S. Islam, M.A. Roni, and R.-U. Jalil Systematic development of self-emulsifying drug delivery systems of atorvastatin with improved bioavailability potential Sci. Pharm. 80 2012 1027 1043
18. S. Khani, and F. Keyhanfar Improved oral bioavalability of mebudipine upon administration in phytosolve and phosal-based formulation (PBF) AAPS PharmSciTech 15 2014 96 102
19. M. Leung, H. Colangelo, and W. Kee Encapsulation of curcumin in cationic micelles suppresses alkaline hydrolysis Langmuir 24 2008 5672 5675
20. K. Maiti, K. Mukherjee, A. Gantait, B.P. Saha, and P.K. Mukherjee Curcumin-phospholipid complex preparation, theraputic evaluation and pharmacokinetic study in rats Int. J. Pharm. 330 2007 155 163
21. T.H. Marczylo, R.D. Verschoyle, D.N. Cooke, P. Morazzoni, W.P. Steward, and A.J. Gescher Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine Cancer Chemoth. Pharmacol. 60 2007 171 177
22. M. Pan, T. Huang, and J. Lin Biotransformation of curcumin through reduction and glucuronidation in mice Drug Metab. Dispos. 27 1999 486 494
23. C. Porter, N. Trevaskis, and W. Charman Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs Nat. Rev. Drug Discovery 6 2007 231 248
24. A. Priev, S. Zalipsky, R. Cohen, and Y. Barenholz Determination of critical micelle concentration of lipopolymers and other amphiphiles: comparison of sound velocity and fluorescent measurements Langmuir 18 2002 612 617
25. X. Ren, X. Mao, L. Cao, K. Xue, L. Si, J. Qiu, A.S. Schimmer, and G. Li Nonionic surfactants are strong inhibitors of cytochrome P450 3A biotransformation activity in vitro and in vivo Eur. J. Pharm. 36 2009 401 411
26. X. Ren, X. Mao, L. Si, L. Cao, H. Xiong, J. Qiu, A.D. Schimmer, and G. Li Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration Eur. J. Pharm. Biopharm. 70 2008 279 288
27. L.L. Schramm Emulsions, Foams, and Suspensions: Fundamentals and Applications 2005 WILEY-VCH Verlag GmbH & Co., KGaA Weinheim
28. R. Sharma, C. Ireson, R. Verschoyle, K. Hill, M. Williams, C. Leuratti, M. Manson, L. Marnett, and W. Steward Effects of dietary curcumin on glutathione-s-transferase and malondialdehyde-DNA adducts in rat liver and colon mucosa: relationship with drug levels Clin. Cancer Res. 7 2001 1452 1458
29. M. Sun, X. Su, B. Ding, X. He, X. Liu, A. Yu, H. Lou, and G. Zhai Advances in nanotechnology-based delivery systems for curcumin Nanomedicine 7 7 2012 1085 1100
30. United States Pharmacopeia 32/ NF 27. 2011.
31. P. Utreja, S. Jain, and A.K. Tiwary Evaluation of biosafety and intracellular uptake of cremophore EL free paclitaxel elastic liposomal formulation Drug Delivery 19 2012 11 20
32. S. Vareed, M. Kakarala, T. Ruffin, J. Crowell, D. Normolle, Z. Djuric, and E. Brenner Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects Cancer Epidemiol. Biomarkers 17 2008 1411 1417
33. J. Wadhwa, A. Nair, and R. Kumria Emulsion forming drug delivery system for lipophilic drugs Acta Pol. Pharm. 69 2012 179 191
34. B. Wahlang, Y.B. Pawar, and A.K. Bansal Identification of permeability-related hurdles in oral delivery of curcumin using the Caco-2 cell model Eur. J. Pharm. Biopharm 77 2011 275 282
35. J. Werling, S. Graham, H. Owen, L. Nair, T. Gonyon, and P. Carter Physicochemical stability of phospholipid-dispersed suspensions of crystalline itraconazole Eur. J. Pharm. Biopharm. 69 2008 1104 1113
36. Y. Xiangrong, W. Wenbin, B. Yueqi, C. Zheng, C. Qiuhong, L. Yuanbo, and H. Shixiang PLGA nanoparticles simultaneously loaded with vincristine sulfate and verapamil hydrochloride: systematic study of particle size and drug entrapment efficiency Int. J. Pharm. 350 2008 320 329
37. M.M. Yallapu, M. Jaggi, and S.C. Chauhan Curcumin nanoformulations: a future nanomedicine for cancer Drug Discovery Today 17 1-2 2012 71 80
38. L. Zhongfa, M. Chiu, J. Wang, W. Chen, W. Yen, P.D. Fan-Harvard, L. Yee, and K.K. Chan Enhancement of curcumin oral absorption and pharmacokinetics of curcuminoids and curcumin metabolites in mice Cancer Chem. Pharm. 69 2012 679 689